

Ring-opening metathesis and ring-closing metathesis of bicyclo[4.2.0]octene-yne: application to the synthesis of tricyclic compounds

Hideaki Wakamatsu,* Satoko Hareyama, and Mitsuhiro Takeshita

Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan

E-mail: hiwaka@tohoku-pharm.ac.jp

Dedicated to Prof. S. Blechert on the occasion of his 65th birthday


Abstract

Ring-opening metathesis and ring-closing metathesis (ROM-RCM) of bicyclo[4.2.0]octene-yne and their application to the synthesis of tricyclic derivatives have been demonstrated using a second-generation ruthenium carbene complex. When bicycloalkene having a propargylamino group as an alkyne tether was reacted with a second-generation ruthenium carbene complex under an ethylene atmosphere, ROM-RCM proceeded to give tricyclic heterocycles in good yield. On the other hand, when the effect of the substituent on the alkyne was examined, cross metathesis (CM) of the alkyne part with ethylene proceeded to provide a conjugated diene derivative.

Keywords: Ring-opening metathesis and ring-closing metathesis, ruthenium, carbene complex, cross metathesis, ethylene, cycloalkene-yne


Introduction

Olefin metathesis contains a cleavage of carbon-carbon double bonds concomitantly with the formation of other ones by a metal carbene complex.¹ Currently, it has become a powerful synthetic method for the formation of carbon-carbon double bonds in the field of synthetic organic chemistry. Enyne metathesis,² which takes place between a double bond and triple bond, is of particular interest. The diene derivative is obtained by enyne metathesis, although a two-carbon unit is thrown away as an ethylene by olefin metathesis. When enyne metathesis is carried out as an intramolecular reaction, the olefin part of enyne is cleaved and its alkylidene part is transferred to an alkyne. As a result, a cyclized diene derivative is obtained (Scheme 1).




Scheme 1. Enyne metathesis.

After the first report of enyne metathesis by Katz and co-workers,³ the progressive results, which contain the total synthesis of stemoamide^{2g} and the effect of ethylene,^{2f} were reported.² Recently, we developed ROM-RCM of cycloalkene-yne.^{4,5} When a metathesis reaction of cycloalkene-yne, whose tether having an alkyne part is connected to the C-1 position of cycloalkene, was carried out in the presence of **1** under an ethylene atmosphere, ROM-RCM proceeded smoothly to provide bicyclic compound **3** in good yield (Scheme 2).




Scheme 2. Ring-Opening Metathesis and Ring-Closing Metathesis of Cycloalkene-yne.

The reaction mechanism of ROM-RCM is shown in Scheme 3.




Scheme 3. Plausible reaction mechanism for ROM-RCM of cycloalkene-yne.

The reaction of the alkyne part of enyne **I** with a ruthenium methylidene complex gives ruthenacyclobutene **II**, which was converted into vinyl carbene complex **III**. If this carbene complex **III** reacts with a cycloalkene part, ruthenacyclobutane **IV** would be formed and it should be converted into **V**. If carbene complex **V** reacts with a vinyl group intramolecularly, ring-closing metathesis would proceed to provide bicyclic compound **VII**, together with a ruthenium methylidene complex. Interestingly, the initial n -membered ring is converted into an $(n + 2)$ -membered ring size in this reaction. The other ring size depends on the chain lengths between the double bond and the triple bond. We recently developed ROM-RCM of cyclobutenylmethylamine **4** having an alkyne moiety in a tether catalyzed by second-generation Grubbs catalyst **1**, and isoquinoline derivatives **5** could be obtained in good yields in a one-step reaction (Scheme 4).^{4d}



Scheme 4. ROM-RCM of cyclobutene-ynes.

Herein we report the synthesis of tricyclic compounds **7** by ROM-RCM of bicyclo[4.2.0]octene-ynes **6** for the further application of our previous development (Scheme 5).




Scheme 5. Plan for synthesis of tricyclic heterocycles.

Results and Discussion

Enynes **6** were prepared according to the synthetic route shown in Scheme 6. Alcohol **9** was synthesized by the literature procedure.⁶ [2+2] cocyclization of silyl enol ether **8** and ethyl propiolate, promoted by ZrCl₄ and followed by treatment with DIBAL-H, gave primary alcohol **9** in 66% yield. Enynes **6a-c** were obtained by a Mitsunobu reaction⁷ of **9** with tosylamide **10** or


11 in good to high yield. Enyne **6d**, having a phenyl group on the terminal alkyne, was synthesized by Sonogashira cross coupling⁸ of **6b** and Iodobenzene.



Scheme 6. Preparation of substrate **6**.

ROM-RCM of **6a** was examined and the results are shown in Table 1. When a reaction of **6a** was carried out in the presence of 20 mol% of ruthenium carbene complex **1** in CH_2Cl_2 under an ethylene atmosphere and reflux for 48 h, compound **12** was obtained in 24% yield (entry 1). Although tricyclic compound **7a** was not obtained, changing a solvent from CH_2Cl_2 to toluene was effective for the synthesis of **12** and conjugated diene derivative **12** was obtained in 90% yield (entry 2).


Table 1. ROM-RCM of **6a**^a



Entry	Solvent	Time (h)	Yield of 12 (%)
1	CH_2Cl_2	48	24
2	Toluene	0.5	90

^aAll reactions were carried out in the presence of 20 mol% **1** under ethylene atmosphere.

Probably, ruthenium carbene complex **1** would react with the alkyne part of **6a** to provide carbene complex **ii**, although a recent study strongly supported the predominance of the initial cyclometallation on an alkene over an alkyne.⁹ Ruthenium carbene complex **ii** reacts with ethylene intermolecularly, not the alkene part of cycloalkene. Then triene derivative **12** would be obtained through ruthenacyclobutane intermediate **iii** (Scheme 7, path a).



Scheme 7. Possible reaction pathway.

Enyne **6b**, which has a retrenched alkyne side chain compared to **6a**, was examined (Scheme 8). When a dichloromethane solution of **6b** was stirred in the presence of 10 mol% of **1** under reflux for 1 h, desilylated tricyclic compound **13** was isolated in 60% yield after the usual workup by column chromatography on silica gel. The crude product was explored by ^1H NMR measurement in order to get to the root of the desilylation. As a result, we could confirm that non-aromatized product **7b** was obtained in 69% yield. Presumably, ROM-RCM of **6b** proceeded to provide **7b**, which was aromatized to **13** during column chromatography on silica gel.

derivative **14** in high yield although remarkable advancement was not observed when the substituent on the alkyne was examined.

Experimental Section

General. The metathesis reactions were carried out under an atmosphere of ethylene (1 atm) unless otherwise mentioned. All other manipulations were carried out under an atmosphere of argon unless otherwise mentioned. Ruthenium complexes were purchased from Aldrich Chemical Company. All other solvents and reagents were purified when necessary using standard procedure. Column chromatography was performed on silica gel 60 N (spherical, neutral, 40-60 μm , Kanto Chemical Co.). IR spectra were recorded on PERKIN ELMER FT-IR 1725X. ^1H and ^{13}C NMR spectra were recorded on JEOL JNM-EX270 (^1H : 270 MHz, ^{13}C : 67.8 MHz) spectrometer. Chemical shift values were reported in ppm (δ) downfield from tetramethylsilane as an internal standard, or residual solvent peak [^1H NMR, CHCl_3 (7.24); ^{13}C NMR, CHCl_3 (77.0)]. Coupling constants (J) are reported in Hertz (Hz). EI mass spectra were measured on JEOL JMN-DX 303/JMA-DA 5000.

General procedure A for metathesis reaction

To a solution of cycloalkene-ynes in CH_2Cl_2 (0.02 M) was added ruthenium carbene complex **1**, and the mixture was refluxed under ethylene atmosphere. Ethylvinyl ether was added to the mixture at 0 $^\circ\text{C}$, and the volatiles were removed under reduce pressure. The residue was purified by column chromatography on silica gel to provide the product.

General procedure B for metathesis reaction

To a solution of cycloalkene-ynes in toluene (0.02 M) was added ruthenium carbene complex **1**, and the mixture was stirred at 80 $^\circ\text{C}$ under ethylene atmosphere. Ethylvinyl ether was added to the mixture at 0 $^\circ\text{C}$, and the volatiles were removed under reduce pressure. The residue was purified by column chromatography on silica gel to provide the product.

[6-(*t*-Butyldimethylsilyloxy)-bicyclo[4.2.0]oct-7-en-7-yl]-methanol (9). To a suspension of ZrCl_4 (1.34 g, 5.73 mmol) in CH_2Cl_2 (20 mL) was added a solution of **8** (1.22 g, 5.73 mmol) in CH_2Cl_2 (9 mL) after the addition of Ethyl propiolate (0.87 mL, 8.60 mmol) at -78 $^\circ\text{C}$, and the reaction mixture was stirred for 20 min. The reaction mixture was warmed to room temperature after addition of Diethyl ether (30 mL) and H_2O (10 mL) at -78 $^\circ\text{C}$, and water phase was separated. The organic phase was washed with saturated NaCl solution, and dried with MgSO_4 . The volatiles were removed under reduce pressure to obtain crude product, which was used directly next reaction. To a solution of the crude product in THF (4.8 mL) was added DIBAL-H (2.9 mL, 2.9 mmol, 1 M THF solution) at -78 $^\circ\text{C}$, and the mixture was stirred for 1 h at the same temperature. Ethyl acetate (6 mL) and saturated potassium sodium tartrate solution (30 mL) was added to the mixture, which was warmed to room temperature and stirred over 12 h. The mixture

was extracted with ethyl acetate. The organic phase was washed with saturated NaCl solution, and dried with MgSO₄. The volatiles were removed under reduce pressure, and the residue was purified by column chromatography on silica gel (Hexane / EtOAc, 3:1) to provide **9** (169.3 mg, 66%); ¹H NMR (270 MHz, CDCl₃) δ 0.09 (s, 3H), 0.10 (s, 3H), 0.86 (s, 9H), 1.39-1.60 (m, 4H), 1.66-1.85 (m, 4H), 2.70-2.72 (m, 1H), 4.14-4.24 (m, 2H), 5.98 (dd, *J* = 1.5, 2.5 Hz, 1H).

***N*-[6-(*t*-Butyldimethylsilyloxy)-bicyclo[4.2.0]oct-7-en-7-ylmethyl]-*N*-but-3-ynyl-*p*-toluenesulfonamide (**6a**).** To a solution of **9** (325.7 mg, 1.21 mmol), **10** (379.6 mg, 1.70 mmol) and PPh₃ (634.7 mg, 2.42 mmol) in THF (12 mL, 0.1 M) was added DEAD (1.1 mL, 2.42 mmol) at 0 °C, and the mixture was stirred at room temperature for 22 h. The volatiles were removed under reduce pressure, and the residue was purified by column chromatography on silica gel (Hexane / Et₂O, 5:1) to provide **6a** (453.8 mg, 79%); IR (neat) ν 3312, 2930, 2856, 2122, 1600, 1346, 1254, 1161, 1100 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 0.06 (s, 3H), 0.07 (s, 3H), 0.85 (s, 9H), 1.26-1.69 (m, 8H), 1.95 (t, *J* = 2.6 Hz, 1H), 2.42-2.51 (m, 5H), 2.59 (s, 1H), 3.42 (tt, *J* = 1.8, 7.8 Hz, 2H), 3.78 (dt, *J* = 18.0, 1.8 Hz, 1H), 3.92 (dt, *J* = 18.0, 1.8 Hz, 1H), 5.58 (d, *J* = 0.8 Hz, 1H), 7.28 (d, *J* = 8.4 Hz, 2H), 7.72 (d, *J* = 8.4 Hz, 2H); ¹³C NMR (67.8 MHz, CDCl₃) δ -2.8, -2.6, 17.6, 18.0, 18.2, 19.3, 21.7, 23.2, 25.9, 32.1, 44.3, 46.6, 49.0, 70.3, 78.4, 81.2, 127.4, 129.8, 132.9, 137.4, 143.5, 147.7; EI-LRMS *m/z* 473 (M⁺), 416, 280, 91, 73; EI-HRMS *m/z* calcd for C₂₆H₃₉O₃NSiS (M⁺) 473.2420, found 473.2430.

***N*-[6-(*t*-Butyldimethylsilyloxy)-bicyclo[4.2.0]oct-7-en-7-ylmethyl]-*N*-prop-2-ynyl-*p*-toluenesulfonamide (**6b**).** To a solution of **9** (206.3 mg, 0.77 mmol), **11a** (225.1 mg, 1.08 mmol) and PPh₃ (403.1 mg, 1.54 mmol) in THF (7 mL, 0.1 M) was added DEAD (0.7 mL, 1.54 mmol) at 0 °C, and the mixture was stirred at room temperature for 24 h. The volatiles were removed under reduce pressure, and the residue was purified by column chromatography on silica gel (Hexane / Et₂O, 5:1) to provide **6b** (346.1 mg, 97%); IR (neat) ν 3248, 2927, 2854, 2116, 1599, 1353, 1253, 1186, 1095 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 0.07 (s, 3H), 0.08 (s, 3H), 0.85 (s, 9H), 1.41-1.55 (m, 8H), 2.00 (t, *J* = 2.4 Hz, 1H), 2.42 (s, 3H), 2.67 (s, 1H), 3.81 (s, 2H), 4.23 (t, *J* = 2.6 Hz, 2H), 5.95 (s, 1H), 7.28 (d, *J* = 8.4 Hz, 2H), 7.74 (d, *J* = 8.4 Hz, 2H); ¹³C NMR (67.8 MHz, CDCl₃) δ -3.3, -3.1, 17.1, 17.5, 17.7, 21.2, 22.7, 25.4, 31.6, 36.1, 42.2, 48.7, 73.5, 76.4, 79.2, 127.4, 129.1, 133.6, 135.9, 143.1, 146.6; EI-LRMS *m/z* 459(M⁺), 402, 266, 91, 73; EI-HRMS *m/z* calcd for C₂₅H₃₇O₃NSiS (M⁺) 459.2263, found 459.2255.

***N*-[6-(*t*-Butyldimethylsilyloxy)-bicyclo[4.2.0]oct-7-en-7-ylmethyl]-*N*-but-2-ynyl-*p*-toluenesulfonamide (**6c**).** To a solution of **9** (169.3 mg, 0.63 mmol), **11b** (198.2 mg, 0.43 mmol) and PPh₃ (344.2 mg, 0.43 mmol) in THF (4 mL, 0.1 M) was added DEAD (0.6 mL, 0.43 mmol) at 0 °C, and the mixture was stirred at room temperature for 48 h. The volatiles were removed under reduce pressure, and the residue was purified by column chromatography on silica gel (Hexane / Et₂O, 4:1) to provide **6c** (245.6 mg, 82%); IR (neat) ν 2929, 2856, 2225, 1600, 1352, 1254, 1163, 1095 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 0.07 (s, 3H), 0.08 (s, 3H), 0.85 (s, 9H), 1.39-1.56 (m, 11H), 2.42 (s, 3H), 2.66 (s, 1H), 3.78 (t, *J* = 2.0 Hz, 2H), 4.14 (tq, *J* = 2.0, 2.3 Hz, 2H), 5.92 (d, *J* = 0.8 Hz, 1H), 7.28 (d, *J* = 8.1 Hz, 2H), 7.74 (d, *J* = 8.1 Hz, 2H); ¹³C NMR (67.8 MHz, CDCl₃) δ -3.2, -2.9, 3.1, 17.4, 17.7, 17.9, 21.4, 23.0, 25.6, 31.9, 36.9, 42.4, 48.9, 71.8,

78.3, 81.5, 127.8, 129.1, 133.2, 136.3, 143.0, 147.2; EI-LRMS m/z 473 (M^+), 416, 280, 91, 73; EI-HRMS m/z caclcd for $C_{26}H_{39}O_3NSiS$ (M^+) 473.2420, found 473.2420.

***N*-[6-(*t*-Butyldimethylsilyloxy)-bicyclo[4.2.0]oct-7-en-7-ylmethyl]-*N*-(3-phenyl-prop-2-ynyl)-*p*-toluenesulfonamide (6d).** To a solution of $Pd(PPh_3)_4$ (25.1 mg, 0.02 mmol) and CuI (4.1 mg, 0.02 mmol) in Et_3N (1 mL, 0.4 M) was added PhI (51 μ L, 0.46 mmol) at room temperature, and the mixture was stirred for 10 min. To the mixture was added **6b** (200.4 mg, 0.43 mmol) in Benzene (1 mL), and the resulting mixture was stirred at the same temperature for 19 h. The volatiles were removed under reduce pressure, and the residue was purified by column chromatography on silica gel (Hexane / Et_2O , 5:1) to provide **6d** (156.8 mg, 68%); IR (neat) ν 2929, 2856, 2242, 1599, 1352, 1254, 1164, 1094 cm^{-1} ; 1H NMR (270 MHz, $CDCl_3$) δ 0.08 (s, 3H), 0.09 (s, 3H), 0.85 (s, 9H), 1.43-1.54 (m, 8H), 2.33 (s, 3H), 2.70 (s, 1H), 3.87 (d, $J = 1.8$ Hz, 2H), 4.44 (d, $J = 2.3$ Hz, 2H), 6.03 (d, $J = 1.0$ Hz, 1H), 7.05 (d, $J = 8.3$ Hz, 2H), 7.20-7.28 (m, 5H), 7.77 (d, $J = 8.3$ Hz, 2H); ^{13}C NMR (67.8 MHz, $CDCl_3$) δ -3.1, -2.8, 17.4, 17.8, 17.9, 21.3, 23.0, 25.7, 31.9, 37.3, 42.8, 49.1, 78.5, 81.9, 85.7, 122.2, 127.7, 128.0, 128.2, 129.4, 131.4, 133.8, 136.1, 143.3, 147.0; EI-LRMS m/z 536 (M^+), 478, 380, 342, 248, 115, 91, 73; EI-HRMS m/z caclcd for $C_{31}H_{41}O_3NSiS$ (M^+) 535.2576, found 535.2576.

***N*-[6-(*t*-Butyldimethylsilyloxy)-bicyclo[4.2.0]oct-7-en-7-ylmethyl]-*N*-(3-methylene-pent-4-enyl)-*p*-toluenesulfonamide (12).** According to general procedure B, a solution of **6a** (33.0 mg, 0.07 mmol) and **1** (5.9 mg, 7 μ mol) in toluene (3.5 mL, 0.02 M) was stirred for 0.5 h to provide **12** (31.6 mg, 90%); IR (neat) ν 2930, 2856, 1597, 1345, 1254, 1160, 1100 cm^{-1} ; 1H NMR (270 MHz, $CDCl_3$) δ 0.04 (s, 3H), 0.06 (s, 3H), 0.84 (s, 9H), 1.26-1.52 (m, 8H), 2.41 (s, 3H), 2.49-2.58 (m, 3H), 3.35 (tt, $J = 2.1, 6.5$ Hz, 2H), 3.78 (dt, $J = 18.1, 2.1$ Hz, 1H), 3.89 (dt, $J = 18.1, 2.1$ Hz, 1H), 4.99 (s, 1H), 5.04 (s, 1H), 5.08 (d, $J = 10.9$ Hz, 1H), 5.28 (d, $J = 17.6$ Hz, 1H), 5.56 (s, 1H), 6.31 (dd, $J = 10.9, 17.6$ Hz, 1H), 7.27 (d, $J = 8.2$ Hz, 2H), 7.71 (d, $J = 8.2$ Hz, 2H); ^{13}C NMR (67.8 MHz, $CDCl_3$) δ -3.1, -2.8, 17.3, 17.8, 17.9, 21.4, 23.0, 25.6, 31.0, 31.9, 43.9, 47.2, 48.7, 78.1, 114.0, 117.5, 127.2, 129.5, 132.2, 137.5, 138.0, 143.0, 143.1, 147.7; EI-LRMS m/z 501 (M^+), 444, 346, 308, 251, 91, 73; EI-HRMS m/z caclcd for $C_{28}H_{43}O_3NSiS$ (M^+) 501.2733, found 501.2732.

2-(*p*-Toluenesulfonyl)-2,3,6,7,8,9-hexahydro-1*H*-benzo[*e*]isoindole (13). According to general procedure A, a solution of **6b** (57.2 mg, 0.12 mmol) and **1** (10.5 mg, 12.4 μ mol) in CH_2Cl_2 (6 mL, 0.02 M) was stirred for 1 h to provide **13** (23.1 mg, 60%); IR (neat) ν 2936, 1596, 1345, 1164 cm^{-1} ; 1H NMR (270 MHz, $CDCl_3$) δ 1.77 (t, $J = 3.2$ Hz, 4H), 2.40 (s, 3H), 2.52 (t, $J = 5.6$ Hz, 2H), 2.72 (t, $J = 5.4$ Hz, 2H), 4.50 (s, 2H), 4.60 (s, 2H), 6.89 (d, $J = 7.9$ Hz, 1H), 6.96 (d, $J = 7.8$ Hz, 1H), 7.31 (d, $J = 8.2$ Hz, 2H), 7.77 (d, $J = 8.2$ Hz, 2H); ^{13}C NMR (67.8 MHz, $CDCl_3$) δ 21.4, 22.6, 22.8, 26.2, 29.2, 52.9, 53.9, 119.3, 127.5, 128.8, 129.7, 131.9, 132.8, 133.8, 134.9, 136.5, 143.5; EI-LRMS m/z 326 (M^+), 172, 91; EI-HRMS m/z caclcd for $C_{19}H_{21}O_2NS$ (M^+) 327.1293, found 327.1274.

***N*-[6-(*t*-Butyldimethylsilyloxy)-bicyclo[4.2.0]oct-7-en-7-ylmethyl]-*N*-(3-methyl-2-methylene-but-3-enyl)-*p*-toluenesulfonamide (14c).** According to general procedure A, a solution of **6c** (63.1 mg, 0.13 mmol) and **1** (11.3 mg, 13.33 μ mol) in CH_2Cl_2 (6.5 mL, 0.02 M) was stirred for 1

h to provide **14c** (47.1 mg, 72%); IR (neat) ν 2930, 2856, 1345, 1254, 1162, 1096 cm^{-1} ; ^1H NMR (270 MHz, CDCl_3) δ 0.02 (s, 3H), 0.03 (s, 3H), 0.82 (s, 9H), 1.26-1.45 (m, 8H), 1.89 (s, 3H), 2.41 (s, 3H), 2.50 (s, 1H), 3.75 (d, $J = 2.1$ Hz, 2H), 4.14 (q, $J = 15.0$ Hz, 2H), 5.02 (s, 1H), 5.14 (s, 1H), 5.23 (s, 2H), 5.29 (s, 1H), 7.27 (d, $J = 8.2$ Hz, 2H), 7.73 (d, $J = 8.2$ Hz, 2H); ^{13}C NMR (67.8 MHz, CDCl_3) δ -3.1, -2.9, 17.4, 17.7, 17.9, 21.2, 21.4, 23.0, 25.6, 31.9, 42.9, 48.7, 49.9, 78.0, 114.0, 115.4, 127.4, 129.4, 131.5, 137.4, 140.6, 141.4, 143.0, 147.4; EI-LRMS m/z 501(M^+), 444, 362, 346, 308, 91, 73; EI-HRMS m/z calcd for $\text{C}_{28}\text{H}_{43}\text{O}_3\text{NSiS}$ (M^+) 501.2733, found 501.2740.

***N*-[6-(*t*-Butyldimethylsilyloxy)-bicyclo[4.2.0]oct-7-en-7-ylmethyl]-*N*-(2-methylene-3-phenylbut-3-enyl)-*p*-toluenesulfonamide (14d)**. According to general procedure B, a solution of **6d** (29.4 mg, 0.05 mmol) and **1** (4.6 mg, 5.47 μmol) in toluene (3 mL, 0.02 M) was stirred for 0.5 h to provide **14d** (27.8 mg, 98%); IR (neat) ν 2930, 2856, 1599, 1344, 1256, 1160, 1094 cm^{-1} ; ^1H NMR (270 MHz, CDCl_3) δ 0.03 (s, 3H), 0.05 (s, 3H), 0.84 (s, 9H), 1.26-1.46 (m, 8H), 2.40 (s, 3H), 2.53 (s, 1H), 3.85 (s, 2H), 4.16 (s, 2H), 5.13 (s, 1H), 5.23 (s, 1H), 5.30 (s, 1H), 5.35 (d, $J = 0.8$ Hz, 1H), 5.38 (d, $J = 1.0$ Hz, 1H), 7.24-7.34 (m, 7H), 7.72 (d, $J = 8.4$ Hz, 2H); ^{13}C NMR (67.8 MHz, CDCl_3) δ -3.0, -2.8, 17.4, 17.8, 18.0, 21.5, 23.0, 25.7, 31.9, 43.1, 48.7, 50.2, 78.1, 115.1, 118.6, 127.4, 127.5, 128.1, 128.1, 129.4, 131.9, 137.6, 140.6, 142.4, 143.0, 147.3, 148.0; EI-LRMS m/z 564 (M^+), 507, 408, 370, 251, 91, 73; EI-HRMS m/z calcd for $\text{C}_{33}\text{H}_{45}\text{O}_3\text{NSiS}$ (M^+) 563.2889, found 563.2868.

References

- (a) Grubbs, R. H., Ed.; *Handbook of Metathesis*, Vol. 1-3; Wiley-VCH: Weinheim, 2003. (b) Fürstner, A., Ed.; *Topics in Organometallic Chemistry*, Vol. 1; Springer-Verlag: Berlin, Heidelberg, 1998. For selected general reviews, see: (c) Vougioukalakis, G. C.; Grubbs, R. H. *Chem. Rev.* **2010**, *110*, 1746. (d) Nolan, S. P.; Clavier, H. *Chem. Soc. Rev.* **2010**, *39*, 3305. (e) Kotha, S.; Lahiri, K. *Synlett* **2007**, 2767. (f) Chauvin, Y. *Angew. Chem. Int. Ed.* **2006**, *45*, 3741. (g) Schrock, R. R. *Angew. Chem. Int. Ed.* **2006**, *45*, 3748. (h) Grubbs, R. H. *Angew. Chem. Int. Ed.* **2006**, *45*, 3760. (i) Hoveyda, A. H.; Zhugralin, A. R. *Nature* **2007**, *450*, 243. (j) Nicolaou, K. C.; Bulger, P. G.; Sarlah, D. *Angew. Chem., Int. Ed.* **2005**, *44*, 4490. (k) Fürstner, A. *Angew. Chem., Int. Ed.* **2000**, *39*, 3012. (l) Grubbs, R. H.; Chang, S. *Tetrahedron* **1998**, *54*, 4413. (m) Schuster M.; Blechert S. *Angew. Chem., Int. Ed.* **1997**, *36*, 2037.
- (a) Mori, M. *Top. Organomet. Chem.* **1998**, *1*, 133. (b) Kotha, S.; Meshram, M.; Tiwari, A. *Chem. Soc. Rev.* **2009**, *38*, 2065. (c) Hansen, E. C.; Lee, D. *Acc. Chem. Res.* **2006**, *39*, 509. (d) Diver, S. T.; Giessert, A. J. *Chem. Rev.* **2004**, *104*, 1317. (e) Poulsen, C. S.; Madsen, R. *Synthesis* **2003**, *1*. (f) Mori, M.; Sakakibara, N.; Kinoshita, A. *J. Org. Chem.* **1998**, *63*, 6082. (g) Kinoshita, A.; Mori, M. *J. Org. Chem.* **1996**, *61*, 8356.
- Katz, T. J.; Sivavec, T. M. *J. Am. Chem. Soc.* **1985**, *107*, 737.

4. (a) Kitamura, T.; Mori, M. *Org. Lett.* **2001**, *3*, 1161. (b) Mori, M.; Kuzuba, Y.; Kitamura, T.; Sato, Y. *Org. Lett.* **2002**, *4*, 3855. (c) Kitamura, T.; Kuzuba, Y.; Sato, Y.; Wakamatsu, H.; Fujita, R.; Mori, M. *Tetrahedron*, **2004**, *60*, 7375. (d) Mori, M.; Wakamatsu, H.; Tonogaki, K.; Fujita, R.; Kitamura, T.; Sato, Y. *J. Org. Chem.* **2005**, *70*, 1066. (e) Wakamatsu, H.; Sato, Y.; Fujita, R.; Mori, M. *Heterocycles* **2006**, *67*, 89. (f) Mori, M.; Wakamatsu, H.; Sato, Y.; Fujita, R. *J. Mol. Catal. A: Chem.* **2006**, *254*, 64. (g) Wakamatsu, H.; Sato, Y.; Fujita, R.; Mori, M. *Adv. Synth. Catal.* **2007**, *349*, 1231.
5. The combination of several metathesis transformations was referred as Ring Rearrangement Metathesis (RRM). For review of RRM, see: Holub, N.; Blechert, S. *Chem. Asian J.* **2007**, *2*, 1064.
6. White, B. H.; Snapper, M. L. *J. Am. Chem. Soc.* **2003**, *125*, 14901.
7. (a) Mitsunobu, O. *Synthesis* **1981**, *1*. (b) Hughes, D. L. *Org. React.* **1992**, *42*, 335.
8. (a) Sonogashira, K.; Tohda, Y.; Hagihara, N. *Tetrahedron Lett.* **1975**, *16*, 4467. (b) Chinchilla, R.; Nájera, C. *Chem. Rev.* **2007**, *107*, 874.
9. Sohn, J.-H.; Kim, K. H.; Lee, H.-Y.; No, Z. S.; Ihee, H. *J. Am. Chem. Soc.* **2008**, *130*, 16506.